AbbVie is scheduled to report third-quarter 2026 results on October 30, with analyst consensus estimating global Rinvoq net revenues near $2.73 billion, reflecting about 25% year-over-year growth from continued uptake across immunology indications. Recent positive Phase 3 data for Skyrizi and real-world evidence for Rinvoq in Crohn’s disease and ulcerative colitis, presented at the American College of Gastroenterology meeting, along with European approvals for vitiligo and alopecia areata, support expectations for sustained momentum. Offsetting factors include intensifying competition from Johnson & Johnson’s Tremfya and other entrants in the inflammatory bowel disease market. Traders will focus on whether actual sales exceed the specific threshold, with the immunology franchise’s performance central to overall top-line results.